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Abstract
Background: Smoking, dietary factors, and alcohol consumption are known life style factors contributing to gastrointestinal
carcinogenesis. Genetic variations in carcinogen handling may affect cancer risk. The multidrug resistance 1(MDR1/ABCB1) gene
encodes the transport protein P-glycoprotein (a phase III xenobiotic transporter). P-glycoprotein is present in the intestinal
mucosal lining and restricts absorption of certain carcinogens, among these polycyclic aromatic hydrocarbons. Moreover, P-
glycoprotein transports various endogenous substrates such as cytokines and chemokines involved in inflammation, and may
thereby affect the risk of malignity. Hence, genetic variations that modify the function of P-glycoprotein may be associated with
the risk of colorectal cancer (CRC). We have previously found an association between the MDR1 intron 3 G-rs3789243-A
polymorphism and the risk of CRC in a Danish study population. The aim of this study was to investigate if this MDR1
polymorphism was associated with risk of colorectal adenoma (CA) and CRC in the Norwegian population.
Methods: Using a case-control design, the association between the MDR1 intron 3 G-rs3789243-A polymorphism and the risk
of colorectal carcinomas and adenomas in the Norwegian population was assessed in 167 carcinomas, 990 adenomas, and 400
controls. Genotypes were determined by allelic discrimination. Odds ratio (OR) and 95 confidence interval (95% CI) were
estimated by binary logistic regression.
Results: No association was found between the MDR1 polymorphism (G-rs3789243-A) and colorectal adenomas or cancer.
Carriers of the variant allele of MDR1 intron 3 had odds ratios (95% CI) of 0.97 (0.72–1.29) for developing adenomas, and 0.70
(0.41–1.21) for colorectal cancer, respectively, compared to homozygous wild type carriers.
Conclusion: The MDR1 intron 3 (G-rs3789243-A) polymorphism was not associated with a risk of colorectal adenomas or
carcinomas in the present Norwegian study group. Thus, this MDR1 polymorphism does not seem to play an important role in
colorectal carcinogenesis in this population.
Published: 27 February 2009
BMC Medical Genetics 2009, 10:18 doi:10.1186/1471-2350-10-18
Received: 3 October 2008
Accepted: 27 February 2009
This article is available from: http://www.biomedcentral.com/1471-2350/10/18
© 2009 Andersen et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Medical Genetics 2009, 10:18 http://www.biomedcentral.com/1471-2350/10/18
Page 2 of 6
(page number not for citation purposes)
Background
Colorectal cancer (CRC) is one of the leading causes of
cancer-related mortality in the Western World, with great
impact on the life quality of the affected persons [1]. Both
genetic and environmental factors contribute to the
pathogenesis, and gene-environmental interactions may
modulate cancer risk. Multiple low-penetrance genes have
been shown to confer susceptibility to CRC [2]. Diet com-
ponents, alcohol consumption, and cigarette smoking are
risk factors for CRC [3-6]. High-fat and low-fibre diets, red
and processed meat consumption, and tobacco are all
sources of carcinogenic heterocyclic amines (HCA) and
polycyclic aromatic hydrocarbons (PAH) [7-9]. Alcohol
consumption and cigarette smoking induce inflammation
and may thereby contribute to carcinogenesis [10].
Genetic factors may influence the individual risk of gas-
trointestinal cancer when exposed to endogenous or exog-
enous carcinogens. The multidrug resistance 1 (MDR1/
ABCB1) gene codes for P-glycoprotein, a membrane-
bound transporter [11,12]. P-glycoprotein is abundant in
the intestine [13,14] and transports a broad spectrum of
substrates to the intestinal lumen [15], thereby constitut-
ing a part of the gastrointestinal barrier that protects the
lining cells against xenobiotics, including possible carcin-
ogens. One of the most potent animal PAH carcinogens,
benzo [a]pyrene, may be a P-glycoprotein substrate [16].
Also various cytokines, such as interleukin-1beta, and
chemokines involved in inflammation seem to be P-glyc-
oprotein substrates [17], thus making a potential link
between P-glycoprotein function and inflammation-
induced carcinogenesis. MDR1 also seems to play a role in
early carcinogenesis [18] by preventing apoptosis in
tumor cells [17,19].
Significant MDR1 gene heterogeneity has been demon-
strated [20,21]. The MDR1 C3435T polymorphism has
been associated with low in vivo P-glycoprotein intestinal
expression and activity in Caucasian subjects [22]. This is
in accordance with the demonstration of an association of
the variant allele with a lower mRNA stability [23]. This
variant allele has been associated with higher risk of vari-
ous clinical conditions [24], gastrointestinal cancers
[25,26], and possibly colorectal cancer [27], although,
generally, numbers of study participants in these studies
have been small. However, results from other studies have
been inconsistent [28-32], indicating that other causal
polymorphism(s) may be implicated. Recently, we have
demonstrated that carriers of the variant allele of MDR1
intron 3 (G-rs3789243-A) were at 1.54-fold higher risk of
colorectal cancer than homozygous wild type carriers
(95% CI: 1.13–2.08) in a case-cohort study nested in the
prospective Danish Diet, Cancer and Health cohort study
(V. Andersen et al, submitted). This variant has previously
been found to be associated with the risk of ulcerative col-
itis by the use of a haplotype tagging approach [33]. So far,
the SNP has no known functional effects [33].
We wished to explore the role of the xenobiotic trans-
porter P-glycoprotein, encoded by the MDR1 gene and
known to transport dietary carcinogens, in CRC etiology.
Nearly all colon cancers begin as benign polyps which
slowly develop into cancer. We speculated that the uptake
of dietary carcinogens via P-glycoprotein may be involved
in this process. Therefore, the role of genetic variation in
MDR1 intron 3 (G-rs3789243-A) in relation to the risk of
developing colorectal adenomas and carcinomas was
assessed in the Norwegian population using a case-con-
trol study of 167 carcinomas, 990 adenomas, and 400
controls.
Methods
The KAM (Kolorektal cancer, Arv og Miljø) cohort is based
on the screening group of the Norwegian Colorectal Can-
cer Prevention study (the NORCCAP study) in the county
of Telemark and a series of clinical CRC cases operated at
Telemark Hospital (Skien) and Ulleval University Hospi-
tal (Oslo) [34,35]. In short, 20.780 healthy men and
women, age 50–64 years of age, drawn at random from
the population registry in Oslo (urban) and the county of
Telemark (mixed urban and rural) were invited to have a
flexible sigmoidoscopy screening examination. The KAM
cohort is based on an ethnically homogeneous group of
Norwegian origin.
The KAM biobank consists of samples from individuals
identified with adenomas in the large intestine (1044
accepted; 991 high- and low-risk adenomas (a high-risk
adenoma being defined as an adenoma measuring at least
10 mm in diameter and/or with villous components and/
or showing severe dysplasia), and 53 hyperplastic polyps),
and controls, defined as individuals with normal findings
at flexible sigmoidoscopy screening (400 accepted),
together with 167 cases identified with colorectal cancer.
All of the participants completed a questionnaire on
demographics, health status, dietary and smoking habits,
alcohol consumption, physical exercise and occupation.
The questionnaire contained information on a family his-
tory of adenomas and carcinomas, and the included cases
and controls had no known personal history of genetic
predisposition. In the present study, blood samples were
available from 167 cases with carcinomas, 990 cases with
adenomas (229 high-risk and 761 low-risk adenomas)
and 400 controls. All participants gave verbal and written
informed consent.
The study was done in accordance with the Helsinki Dec-
laration. The Regional Ethics Committee and the Data
Inspectorate approved the KAM study. The ID number for
the study is NCT00119912 at ClinicalTrials.gov [36].BMC Medical Genetics 2009, 10:18 http://www.biomedcentral.com/1471-2350/10/18
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The distribution of age, gender, smoking, and alcohol
consumption among cases and controls are shown in
Table 1.
Genomic DNA was isolated from blood samples accord-
ing to standard procedures [37] with minor modifications
as already described [38]. All analyses were run blinded to
the case-control status. MDR1  G-rs3789243-A [Gen-
Bank:rs3789243]genotyping was performed on an
Mx3000 machine (Stratagene, La Jolla, CA, USA), using
allelic discrimination with TaqMan chemistry, as earlier
described [39]. In short, QPCR was done in 25 μl reac-
tions including 20 ng DNA and 900 nM primers and 200
nM probes with locked nucleic acid (LNA) incorpora-
tions. QPCR was run for 50 cycles with split annealing
and elongation (62°C and 72°C, respectively). Controls
were included in each run. Within each of the three geno-
type groups, 20 randomly selected samples were repeated
to confirm reproducibility.
The genotype frequencies were compared using a logistic
regression model, measured as odds ratio (OR) with 95%
confidence interval (CI). Two separate ORs were calcu-
lated; one crude (OR^a) and one adjusted for age and gen-
der (OR^b). In addition we analyzed for carriers of the
polymorphism separately. MiniTab Statistical Software,
Release 13.1 Xtra (Minitab Inc.) for Windows was used for
the statistical calculations Given the allele frequency of
0.5, we had 80% chance of detecting an OR of approxi-
mately 1.7 in carcinomas and 1.5 in adenomas at a 5%
significance level [40].
Results
Characteristics of the study population and risk factors for
CRC are shown in Table 1. Women were more frequent
among the controls than among cases. Smoking was more
frequent among cases than among controls. Moreover, the
CRC cases were older than the controls. The genotype dis-
tribution among the controls did not deviate from Hardy-
Weinberg equilibrium. No association was found
between the MDR1 polymorphism (G-rs3789243-A) and
the risk of colorectal adenomas or cancer (Table 2). Carri-
ers of the variant allele in MDR1 intron 3 had ORs (95%
CI) of 0.96 (0.72–1.29) for developing adenomas, and
0.70 (0.41–1.21) for developing colorectal cancer, respec-
tively, compared to homozygous wild type carriers.
Discussion
We found no associations between the studied MDR1 pol-
ymorphism and the risk of colorectal adenomas or carci-
nomas in the present Norwegian study group. The risk of
colorectal adenomas and carcinomas were not different
for homozygous or heterozygous carriers of the variant
genotype of MDR1  G-rs3789243-A compared with the
homozygous wild type carriers. A power calculation
showed that we had 80% chance of detecting an OR of
approximately 1.7 in carcinomas and 1.5 in adenomas.
The statistical power to look into interactions was there-
fore limited, and interaction studies were therefore not
done.
MDR1 genotypes have previously been studied in relation
to colorectal cancer susceptibility [27,41,42]. In contrast
to the present study, variant allele carriers of the MDR1 G-
rs3789243-A polymorphism have previously been associ-
ated with a risk of colorectal cancer in the Danish popula-
tion (V. Andersen et al, submitted) and of ulcerative colitis
in the Scottish population [33]. In the Danish study, car-
riers of the variant allele were at 1.54-fold higher risk of
Table 1: Characteristics of study participants with colorectal carcinomas and high- and low-risk adenomas and healthy controls, in 
total 1557 subjects.
Colorectal carcinomas High-risk adenomas Low-risk adenomas Controls
No. of subjects 167 229 761 400
Gender
Male, No (%) 91 (56) 151 (66) 455 (60) 157 (39)
Female, No (%) 76 (44) 78 (34) 306 (40) 243 (61)
Age at inclusion, median 69 (51–86) 57 (53–63) 57 (51–63) 53 (50–63)
BMI, median 25 (19–31) 26 (21–33) 27 (21–32) 26 (21–32)
Red meat, g/day, median 24 (5–76) 27 (7–86) 27 (5–90) 25 (5–95)
Smoking status
Never, No (%) 39 (33) 52 (27) 206 (32) 156 (47)
Ever, No (%) 80 (67) 140 (73) 448 (68) 178 (53)
Observed median values (5–95 percentiles) or percents of potential colorectal cancer confounders among cases and controls.BMC Medical Genetics 2009, 10:18 http://www.biomedcentral.com/1471-2350/10/18
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CRC compared with wild type carriers (95% CI: 1.13–
2.08).
The  MDR1  C3435T polymorphism was studied in a
Polish study population [27]. They found higher risk of
CRC among variant carriers than homozygous wildtype
carriers in a subgroup of younger persons. However, as the
result was based on a subgroup consisting of about 50 per-
sons the findings need to be replicated in a larger study.
Furthermore, no association between this polymorphism
and colon cancer was reported in a Korean study popula-
tion [41].
Several factors may contribute to the differences seen
between the studies. First of all, the first report of genetic
effects is likely to represent an overestimated odds ratios
due to reporting bias [43]. Therefore, the association may
be real but not reproduced due to a weak gene effect and
limited power to detect such small gene effects in the Nor-
wegian replication study.
Population heterogeneity may also contribute. However,
although  MDR1  shows a high degree of heterogeneity
between different population [20,21,44], it may be sug-
gested that the Norwegian, Scottish and Danish popula-
tion may share some common genetic background as it
seems to be the case for CARD15 polymorphisms in Euro-
pean populations [45-47], where a low frequency of the
CARD15 variants in the Northern countries compared to
the rest of Europe has been demonstrated.
Furthermore, differences in carcinogenic exposure may
modify the inherent risk associated with genetic suscepti-
bility. For instance, the average monthly intake of alcohol
was 11 units, corresponding to 88 g alcohol per month
among the controls in the present Norwegian [38] cohort,
whereas the mean alcohol intake was 390 g per month
among the controls in the Danish cohort [48]. Corre-
spondingly, 47% and 34% of the controls were never
smokers in the Norwegian and Danish studies, respec-
tively. However, due to the restricted sample size such dif-
ferences were not elaborated.
Conclusion
The MDR1 G-rs3789243-A polymorphism was not associ-
ated with risk of colorectal adenomas or carcinomas in the
present Norwegian study group, indicating that this poly-
morphism does not play an important role in the colorec-
tal carcinogenesis in the Norwegian population.
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Table 2: Odds Ratios for Colorectal Cancers and Colorectal Adenomas including high- and low-risk adenomas for MDR1 G-rs3789243-A
NCase NControl ORa 95% CI ORb 95% CI
Colorectal Cancer
GG 50 101 1.00 - 1.00 -
GA 78 190 0.80 (0.53–1.22) 0.79 (0.44–1.41)
AA 39 104 0.73 (0.45–1.20) 0.55 (0.27–1.12)
GA and AA 117 294 0.78 (052–1.15) 0.70 (0.41–1.21)
Colorectal Adenomas
GG 253 101 1.00 - 1.00 -
GA 482 190 1.01 (0.76–1.35) 0.98 (0.73–1.35)
AA 234 104 0.90 (0.65–1.24) 0.93 (0.65–1.33)
GA and AA 716 294 0.97 (0.74–1.27) 0.96 (0.72–1.29)
High-risk adenomas
GG 61 101 1.00 - 1.00 -
GA 109 190 0.95 (0.64–1.41) 1.08 (0.69–1.70)
AA 54 104 0.86 (0.54–1.36) 0.98 (0.58–1.64)
GA and AA 163 294 0.92 (0.63–1.33) 1.04 (0.68–1.59)
Low-risk adenomas
GG 192 101 1.00 - 1.00 -
GA 373 190 1.03 (0.77–1.39) 0.98 (0.71–1.36)
AA 180 104 0.91 (0.65–1.28) 0.93 (0.64–1.36)
GA and AA 553 294 0.99 (0.75–1.31) 0.97 (0.71–1.32)
aCrude.
bAdjusted for age and gender.BMC Medical Genetics 2009, 10:18 http://www.biomedcentral.com/1471-2350/10/18
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